Back to top
more

TherapeuticsMD (TXMD)

(Real Time Quote from BATS)

$1.80 USD

1.80
6,340

+0.01 (0.56%)

Updated Jul 26, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in TherapeuticsMD (TXMD) Stock?

by Zacks Equity Research

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

    Options Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock

    by Zacks Equity Research

    Investors in TherapeuticsMD (TXMD) need to pay close attention to the stock based on moves in the options market lately.

      Implied Volatility Surging for TherapeuticsMD, Inc. (TXMD) Stock Options

      by Zacks Equity Research

      Investors in TherapeuticsMD, Inc. (TXMD) need to pay close attention to the stock based on moves in the options market lately.

        TherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher

        by Zacks Equity Research

        TherapeuticsMD, Inc. (TXMD) moved big last session, as its shares jumped almost 6% on the day.

          Are Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock?

          by Zacks Equity Research

          Investors in TherapeuticsMD (TXMD) need to pay close attention to the stock based on moves in the options market lately.

            Are Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock?

            by Zacks Equity Research

            TherapeuticsMD (TXMD) warrants investors' attention based on moves in the options market lately.

              Are Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock?

              by Zacks Equity Research

              Options traders are pricing in a big move for TherapeuticsMD (TXMD) shares as it has huge implied volatility.

                TherapeuticsMD Falls on Likely Delay in TX-004HR Approval

                by Zacks Equity Research

                Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July

                  TherapeuticsMD's Rejoice Study Data Published in Journal

                  by Zacks Equity Research

                  TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.